ATE181668T1 - Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall - Google Patents

Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall

Info

Publication number
ATE181668T1
ATE181668T1 AT91908623T AT91908623T ATE181668T1 AT E181668 T1 ATE181668 T1 AT E181668T1 AT 91908623 T AT91908623 T AT 91908623T AT 91908623 T AT91908623 T AT 91908623T AT E181668 T1 ATE181668 T1 AT E181668T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
atrial fibrillation
treat atrial
prevent stroke
stroke
Prior art date
Application number
AT91908623T
Other languages
English (en)
Inventor
Alberto Julio Kaumann
Francis David King
Original Assignee
Smith Kline French Lab
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab, Beecham Group Plc filed Critical Smith Kline French Lab
Application granted granted Critical
Publication of ATE181668T1 publication Critical patent/ATE181668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT91908623T 1990-04-26 1991-04-24 Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall ATE181668T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009389A GB9009389D0 (en) 1990-04-26 1990-04-26 Treatment

Publications (1)

Publication Number Publication Date
ATE181668T1 true ATE181668T1 (de) 1999-07-15

Family

ID=10675031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908623T ATE181668T1 (de) 1990-04-26 1991-04-24 Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall

Country Status (14)

Country Link
EP (1) EP0526540B1 (de)
JP (2) JPH05509293A (de)
AT (1) ATE181668T1 (de)
AU (1) AU653521B2 (de)
CA (1) CA2081344C (de)
DE (1) DE69131398T2 (de)
DK (1) DK0526540T3 (de)
ES (1) ES2134774T3 (de)
GB (1) GB9009389D0 (de)
GR (1) GR3031042T3 (de)
IE (1) IE911383A1 (de)
PT (1) PT97477B (de)
WO (1) WO1991016045A2 (de)
ZA (1) ZA913071B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128172A1 (en) 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
EP0664794A1 (de) * 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl-carbonsäure ester/amide von kondensierten ring-systemen als 5-ht4-rezeptor antagonisten
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
CA2160420A1 (en) * 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
BR0113073A (pt) * 2000-08-07 2004-06-22 Glaxosmithkline Lab Sas Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP2153830A1 (de) * 2008-08-07 2010-02-17 Sanofi-Aventis Verwendung von Dronedaron zur Herstellung eines Medikaments zur Prävention von Schlaganfällen oder transienten ischämischen Anfällen
PL3176164T3 (pl) 2014-07-30 2020-05-18 Aetas Pharma Co. Ltd. Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4731643A (en) * 1985-10-21 1988-03-15 International Business Machines Corporation Logic-circuit layout for large-scale integrated circuits

Also Published As

Publication number Publication date
WO1991016045A2 (en) 1991-10-31
CA2081344A1 (en) 1991-10-27
EP0526540B1 (de) 1999-06-30
DE69131398D1 (de) 1999-08-05
GR3031042T3 (en) 1999-12-31
WO1991016045A3 (en) 1991-12-26
ZA913071B (en) 1992-11-25
PT97477B (pt) 1998-08-31
EP0526540A1 (de) 1993-02-10
DE69131398T2 (de) 2000-03-02
CA2081344C (en) 2003-10-21
AU653521B2 (en) 1994-10-06
JPH05509293A (ja) 1993-12-22
IE911383A1 (en) 1991-11-06
PT97477A (pt) 1992-01-31
JP2003267890A (ja) 2003-09-25
GB9009389D0 (en) 1990-06-20
AU7768091A (en) 1991-11-11
ES2134774T3 (es) 1999-10-16
DK0526540T3 (da) 1999-11-22

Similar Documents

Publication Publication Date Title
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
NO924619L (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
ATE233558T1 (de) Verwendung von strontiumsälze zur behandlung von arthrose
DE3855489D1 (de) Behandlung von Hautfalten
EP0693928A4 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
DE69422052D1 (de) Vorrichtung zum erzeugen von elektroschocks optimaler dauer zur behandlung von herzarrhythmien
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
DE69131398D1 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69133390D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung von hämorragischem schlaganfall
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69132782D1 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
ATE69163T1 (de) Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
DE69004924D1 (de) Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE96039T1 (de) Arzneimittel und ihre verwendung zur behandlung von parasitosen.
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee